UBS Group
IMMX icon

UBS Group’s Immix Biopharma IMMX Stock Holding History

UBS Group’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Buy
1,941,817
+1,864,985
+2,427% +$17.3M ﹤0.01% 2679
2026
Q1 		$700K Buy
76,832
+18,233
+31% +$134K ﹤0.01% 5825
2025
Q4 		$306K Buy
58,599
+56,659
+2,921% +$233K ﹤0.01% 6352
2025
Q3 		$4.05K Sell
1,940
-12,032
-86% -$28.9K ﹤0.01% 8980
2025
Q2 		$28.9K Buy
13,972
+3,851
+38% +$7.75K ﹤0.01% 8188
2025
Q1 		$17K Sell
10,121
-4,087
-29% -$7.71K ﹤0.01% 8335
2024
Q4 		$31.3K Buy
14,208
+8,062
+131% +$14.7K ﹤0.01% 7573
2024
Q3 		$9.16K Buy
6,146
+2,992
+95% +$6.02K ﹤0.01% 7800
2024
Q2 		$6.25K Sell
3,154
-2,104
-40% -$4.83K ﹤0.01% 7935
2024
Q1 		$16.1K Buy
5,258
+2,630
+100% +$10.2K ﹤0.01% 7017
2023
Q4 		$18.2K Buy
+2,628
New +$11.9K ﹤0.01% 7162
2023
Q2 		– Sell
-2,301
Closed -$4.19K – 9231
2023
Q1 		$4.19K Sell
2,301
-2,386
-51% -$5.27K ﹤0.01% 8222
2022
Q4 		$10.7K Sell
4,687
-7,317
-61% -$9.75K ﹤0.01% 8473
2022
Q3 		$16K Buy
12,004
+7,667
+177% +$16.8K ﹤0.01% 7689
2022
Q2 		$11K Buy
+4,337
New +$8.47K ﹤0.01% 7811
2022
Q1 		– Sell
-32,649
Closed -$116K – 10539
2021
Q4 		$116K Buy
+32,649
New +$112K ﹤0.01% 6172

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group's IMMX Position: Q2 2026 in Review

UBS Group increased its Immix Biopharma (IMMX) stake by 2,427% in Q2 2026, buying an estimated $17.3M and bringing the position to 1,941,817 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

UBS Group first reported a position in IMMX in Q4 2021 and has held it in 16 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • UBS Group held 1,941,817 shares of Immix Biopharma worth $20M as of Q2 2026.
  • UBS Group bought 1,864,985 Immix Biopharma shares in Q2 2026, an estimated $17.3M.
  • Immix Biopharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2679 holding.
  • UBS Group first reported a position in Immix Biopharma in Q4 2021 and has held it in 16 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.